Community versus institutionalised care for people with severe mental illness in five countries in Southeast Europe: pooled analysis of five randomised trials.
Laura Shields-Zeeman, Filip Smit, Ben Wijnen, Catharina Roth, Michel Wensing, Ionela Petrea, RECOVER-E consortium, Felix Bolinski, Stojan Bajraktarov, Jovo Dedovic, René Keet, Martina Rojnic Kuzman, Vladimir Nakov, Raluca Nica, Antoni Novotni
Abstract
Open AccessBACKGROUND: The RECOVER-E project implemented community-based mental healthcare (CMH) oriented at functional recovery in people with schizophrenia, bipolar and severe major depressive disorder in five countries: Bulgaria, Croatia, Montenegro, North Macedonia and Romania, with the aim to shift care from institutions to communities. OBJECTIVE: To evaluate the effectiveness of CMH under real-world circumstances across various healthcare ecologies and contexts. METHODS: A randomised comparison of CMH versus treatment as usual (TAU) based on pooled data from all five RECOVER-E trials (N=931). Outcomes were personal and social role functioning (WHO Disability Assessment Schedule, WHODAS 2.0) and health-related quality of life (EuroQoL-5 Dimensions-3 Levels) at baseline, 12 and 18 months postbaseline. Intention-to-treat analysis was conducted with mixed modelling and a sensitivity analysis adjusted for the impact of COVID-19 on healthcare delivery and outcomes. FINDINGS: At 18-month follow-up, CMH had a 4.55 lower WHODAS disability score than TAU, which was significant (b=-4.55, SE=1.21, z=-3.75, p<0.001), and improved quality of life by 0.07 utility (b=0.07, SE=0.014, z=4.56, p<0.001) equivalent to an additional 25 days in full health. Similar effects were observed in each of the five countries and for all WHODAS subdomains (cognition, mobility, self-care, getting along with people, life activities, participation). Sensitivity analyses adjusting for the confounding effect of COVID-19 showed similar effects. CLINICAL IMPLICATIONS: Recovery-oriented CMH for people with severe mental illness was effective in improving functioning and quality of life for people with schizophrenia, bipolar disorder and severe depression in five South-Eastern European countries and could be implemented across different health systems. TRIAL REGISTRATION NUMBERS: Bulgaria: NCT03922425, Croatia: NCT03862209, Macedonia: NCT03892473, Montenegro: NCT03837340, Romania: NCT03884933.